fiercepharma
Cannabadiol (CBD) products have been in news a lot recently, but what does it take to bring a CBD product to market for an unmet medical need? This webinar will discuss development considerations for CBD and other cannabis-derived products from a clinical, preclinical (pharmacology/toxicology), CMC, and regulatory perspective.
Watch Now
Premier Research
This webinar will address these and other critical questions and will pave the way to strategic planning for compliance with the EU MDR. New product development teams will discover that the timeline for MDR is extremely limited compared to existing products on the market. Post-market surveillance teams will discover the implications of the Post-Market Clinical Follow-up requirement and the European Database on Medical Devices.
Watch Now
Use of non-human primates (NHPs) continues to be necessary as part of the drug development process for various reasons, including current regulatory requirements and scientific justifications of human relevance, to ensure the safety of new pharmaceuticals in humans.
Watch Now
Systechone
The cost of returned medicines is estimated to be between $5-10 billion per year in the US alone. However, pharmaceutical companies are struggling to streamline the data flow and verification of returned saleable goods.
Watch Now